Sakaguchi et al. demonstrated that NPM1-mutant AML with a low FLT3-ITD allelic ratio is not associated with favorable outcomes, and survival of patients with this mutation is improved by allogeneic HCT26. The gene discussed is NPM1; the disease is acute myeloid leukemia.